Arcturus Therape Stock Price, News & Analysis

Arcturus Therapeutics (Nasdaq: ARCT) announced its participation in several upcoming investor conferences, highlighting its focus on mRNA medicines and vaccines. Key events include the Citi’s 17th Annual BioPharma Conference on September 6, 2022, and the Wells Fargo Virtual Healthcare Conference on September 9, 2022, among others. The company emphasizes its innovative technologies and diverse pipeline of therapies targeting infectious diseases and rare liver and respiratory conditions.

Arcturus Therapeutics has secured a $63.2 million award from the Biomedical Advanced Research and Development Authority (BARDA) to advance its pandemic influenza vaccine program utilizing its self-amplifying mRNA platform. The funding will span three years, covering preclinical through Phase 1 studies. This low-dose, freeze-dried vaccine aims to enhance pandemic preparedness with demonstrated safety and efficacy from previous COVID-19 trials. The initiative aligns with U.S. government strategies for rapid response to pandemic threats.

Arcturus Therapeutics (NASDAQ: ARCT) has released encouraging results from its ongoing ARCT-154 booster clinical trial, showing significant neutralizing antibody responses against Omicron variants for at least six months post-vaccination. Data revealed geometric mean fold rises (GMFR) of neutralizing antibodies: BA.1 (22-52), BA.2 (25-55), and BA.5 (9-24), indicating a strong immune response. The low-dose (5 mcg) booster showcased durability and breadth of response, highlighting Arcturus' innovative mRNA technology as a promising platform for infectious disease vaccines.

Arcturus Therapeutics (ARCT) announced encouraging data from its ARCT-154 booster study, revealing a 44-fold increase in neutralizing antibodies against Omicron BA.1 and a 39-fold increase against BA.2 at Day 91 post-vaccination. The company also shared new stability data for its lyophilized vaccine platform, showing room temperature stability for 4 days and refrigerator stability for 6 months. The European Commission granted Orphan Medicinal Product Designation to ARCT-810 for OTC deficiency, promising support for its development. Financial results show revenues of $27.1 million, a significant increase from previous years.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announces the release of its financial results for Q2 2022 on August 9, 2022, after market close. A conference call will follow at 4:30 PM EDT. The company focuses on developing infectious disease vaccines and treatments for rare liver and respiratory diseases using its proprietary mRNA technologies. Notable collaborations include partnerships with Janssen Pharmaceuticals and Ultragenyx Pharmaceutical. For more information, visit www.ArcturusRx.com.

Arcturus Therapeutics (NASDAQ: ARCT) announced that its Board of Directors approved stock options for 48,200 shares to seven new employees. These options, granted under Nasdaq Rule 5635(c)(4), have an exercise price of $12.26 per share, based on the closing stock price from June 16, 2022. The options will vest over four years, with a portion vesting annually. Arcturus is focused on developing mRNA medicines and vaccines for infectious diseases and rare liver and respiratory conditions.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced stock option grants totaling 38,800 shares to five new employees as an inducement for their acceptance of employment. The options have an exercise price of $16.84 per share, the closing price on May 16, 2022. They will vest over four years, with 25% vesting after the first year and the remainder monthly over the next three years. This decision aligns with Nasdaq’s inducement grant exception and highlights Arcturus' ongoing commitment to attracting talent in the mRNA medicine sector.

Arcturus Therapeutics reported significant advancements in its vaccine development against COVID-19, showcasing a 54-fold and 46-fold increase in neutralizing antibodies for Omicron BA.1 and BA.2 with its booster ARCT-154. Financially, the company posted $5.2 million in revenue for Q1 2022, up from $2.1 million year-over-year. Despite this, a net loss of $51.2 million was reported. Arcturus plans to initiate a global registrational booster trial for ARCT-154 soon, supported by a solid cash position of $319.7 million.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) reported promising results from its Phase 1/2 booster trial for ARCT-154, showing sustained neutralizing antibody activity against SARS-CoV-2 for at least three months post-vaccination. The study involved 12 participants receiving a low-dose booster (5 mcg) after two primary doses of Comirnaty®. Results indicated a 30-fold enhancement in neutralizing antibodies against the D614G variant and 24-fold against the Beta variant at three months. Preparations for a pivotal Phase 3 booster trial have been initiated.